Nectar Lifescience Ltd
NSE: NECLIFE BSE: 532649
₹10.26
+0.12 (1.18%)
Fri, 06 Nov 2026, 07:48 pm
Market Cap (in Cr)199.12
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KNectar Lifescience Ltd Company History
1995
- Nectar Lifesciences Limited was incorporated as Surya Medicare Limited
- PSIDC invested in 33,30,000 Equity Shares of the company
1996
- The company proposed a public issue of 6,400,000 Equity Shares
- The company filed the offer document with SEBI
1997
- The company commenced business with the commercial production of Oral Bulk Drugs
1998
- The project was fully completed and the company started production of Sterile Bulk Drugs
1999
- The company added formulation facilities by setting up a vial filling section
2000
- The company undertook an expansion increasing the installed capacity of the plant
2001
- Swiss Technology Venture Capital Fund invested Rs 64 million
- The company installed a new Crystalline section
- The new Crystalline section commenced production in October
2002
- The subsidiary Chempharma was incorporated under the laws of Sri Lanka
2003
- The entire shareholding of PSIDC was bought back by the Promoters
- The company filed the Draft Red Herring Prospectus with SEBI
2004
- The company changed its name to Nectar Lifesciences Limited
- The company planned a public issue of 3,870,000 Equity Shares
2005
- The Promoters acquired all the shares held by Swisstech
2007
- Mr Basant Kumar Goswami was appointed as an additional director Independent director
2008
- The Company split its face value from Rs10 to Rs1
2009
- The company recommended a Final Dividend of Re 0.10 per equity share
- Nectar Lifesciences elevated to the rank of 365 in the list of India's top companies
2010
- The Company declared an interim dividend of Re 0.25 per equity share
- NecLife granted Certificate of Suitability for Cefuroxime Axetil in European Union
2011
- NecLife announced receipt of Japanese MOH approval for Cefuroxime Axetil
- NecLife announced receipt of South Africa MCC approval for Ceftriaxone
- The Company recommended a 10% Final Dividend
- NecLife received European cGMP Approval for its Cephalosporin Formulation Facility
2012
- NecLife granted Certificate of Suitability for Cefuroxime Sodium in European Union
- The Company recommended a 10% Final Dividend
- Mr Harparkash Singh Gill was appointed as a Wholetime Director designated as President Operation and Director
2013
- Mr Dinesh Dua was appointed as an Additional Director and Wholetime Director designated as Chief Executive Officer
2014
- Mr Sanjiv Goyal received the Outstanding Entrepreneurship of the Year award from Asia Pacific Enterprise Awards
- NecLife received European cGMP Approval for its Orals and Injectables Cephalsporins FDF Facility
2015
- Nectar Lifesciences Ltd was honoured with the NECA 2015 Award.
2019
- Nectar Biopharma launched a generic diabetes treatment drug in India.
